ACTION REQUEST

Subject: Subcontract Agreement between the University of Michigan and FibrosIX Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Committee and agreed to by the parties involved.

This proposed agreement (\"Agreement\") falls under the State of Michigan Conflict of Interest Statute because Professor Scott Larsen is an employee of the University of Michigan (\"University\") and a partial owner of FibrosIX Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents (\"Regents\") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Scott Larsen, a Research Professor in the Department of Medicinal Chemistry and Co-Director of the Vahlteich Medicinal Chemistry Core, is a partial owner of a for-profit company called FibrosIX Inc. (the \"Company\`). The Company wishes to fund a National Institutes of Health (prime) SBIR Phase I project entitled \"Demonstrating the efficacy of CCG-257081 to inhibit radiation-induced lung fibrosis in mice\" (ORSP #20-PAF04004) in the Department of Medicinal Chemistry under the direction of Dr. Larsen. The purpose of this project is to test the efficacy of the novel compound CCG-257081 to inhibit radiation induced lung fibrosis in mice.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed $20,500. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Larsen to use his expertise and University laboratory, as well as other University resources, to incorporate compound CCG-257081 as a standard component of all bleomycin-containing chemotherapy regimens to allow oncologists to treat patients with the full course of bleomycin treatment, resulting in reduced mortality and improved patient outcomes.
Recommendations:

This matter has been reviewed and approved by the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into this Agreement with FibrosIX Inc.

Respectfully submitted,

Rebecca Cunningham
Vice President for Research

May 2020